The mouse model for congenital TTP [19] and the rat model for acquired TTP [21] were valuable in demonstrating the efficacy of recombinant ADAMTS13 as a novel therapy for both forms of the disease. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.